As of close of business last night, Enfusion Inc’s stock clocked out at $9.26, down -0.64% from its previous closing price of $9.32. In other words, the price has decreased by -$0.06 from its previous closing price. On the day, 1083489 shares were traded.
Ratios:
To gain a deeper understanding of ENFN’s stock, we examine its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 22.98 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 55.23. For the most recent quarter (mrq), Quick Ratio is recorded 3.44 and its Current Ratio is at 3.44. In the meantime, Its Debt-to-Equity ratio is 0.29 whereas as Long-Term Debt/Eq ratio is at 0.21.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Goldman on February 28, 2024, Downgraded its rating to Sell and sets its target price to $8 from $9 previously.
On January 30, 2024, JP Morgan Downgraded its rating to Underweight which previously was Neutral and also lowered its target price recommendation from $11 to $9.
On November 07, 2023, UBS started tracking the stock assigning a Neutral rating and target price of $9.UBS initiated its Neutral rating on November 07, 2023, with a $9 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Feb 29 ’24 when Campobasso Matthew sold 108 shares for $8.73 per share. The transaction valued at 943 led to the insider holds 30,840 shares of the business.
Gutowski Valeria sold 27 shares of ENFN for $236 on Feb 29 ’24. The Chief Accounting Officer now owns 17,570 shares after completing the transaction at $8.73 per share. On Jan 10 ’24, another insider, Somers Deirdre, who serves as the Director of the company, sold 1,770 shares for $8.65 each. As a result, the insider received 15,310 and left with 34,471 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ENFN now has a Market Capitalization of 832.21M and an Enterprise Value of 812.04M. As of this moment, Enfusion’s Price-to-Earnings (P/E) ratio for their current fiscal year is 191.32, and their Forward P/E ratio for the next fiscal year is 31.57. For the stock, the TTM Price-to-Sale (P/S) ratio is 4.69 while its Price-to-Book (P/B) ratio in mrq is 15.24. Its current Enterprise Value per Revenue stands at 4.65 whereas that against EBITDA is 37.02.
Stock Price History:
Over the past 52 weeks, ENFN has reached a high of $11.56, while it has fallen to a 52-week low of $7.37. The 50-Day Moving Average of the stock is 8.71, while the 200-Day Moving Average is calculated to be 9.21.
Shares Statistics:
It appears that ENFN traded 357.12K shares on average per day over the past three months and 750.66k shares per day over the past ten days. A total of 88.33M shares are outstanding, with a floating share count of 45.04M. Insiders hold about 49.01% of the company’s shares, while institutions hold 60.44% stake in the company. Shares short for ENFN as of Feb 29, 2024 were 1.67M with a Short Ratio of 4.68, compared to 1.7M on Jan 31, 2024. Therefore, it implies a Short% of Shares Outstanding of 1.89% and a Short% of Float of 3.60%.
Earnings Estimates
As of right now, 8 analysts gave their recommendation on the stock of the company. On average, analysts expect EPS of $0.05 for the current quarter, with a high estimate of $0.06 and a low estimate of $0.03, while EPS last year was $0.04. The consensus estimate for the next quarter is $0.04, with high estimates of $0.04 and low estimates of $0.03.
Analysts are recommending an EPS of between $0.16 and $0.13 for the fiscal current year, implying an average EPS of $0.15. EPS for the following year is $0.23, with 7 analysts recommending between $0.26 and $0.17.
Revenue Estimates
In the current quarter, 7 analysts expect revenue to total $46.49M. It ranges from a high estimate of $47M to a low estimate of $44.45M. As of the current estimate, Enfusion Inc’s year-ago sales were $40.52M, an estimated increase of 14.70% from the year-ago figure. For the next quarter, 7 analysts are estimating revenue of $47.61M, an increase of 14.60% less than the figure of $14.70% in the same quarter last year. There is a high estimate of $48.14M for the next quarter, whereas the lowest estimate is $46.95M.
A total of 8 analysts have provided revenue estimates for ENFN’s current fiscal year. The highest revenue estimate was $174.1M, while the lowest revenue estimate was $172.5M, resulting in an average revenue estimate of $174.53M. In the same quarter a year ago, actual revenue was $150.35M, up 16.10% from the average estimate. Based on 8 analysts’ estimates, the company’s revenue will be $205.58M in the next fiscal year. The high estimate is $210M and the low estimate is $204.19M. The average revenue growth estimate for next year is up 17.80% from the average revenue estimate for this year.
